Zobrazeno 1 - 10
of 628
pro vyhledávání: '"Mease PJ"'
Publikováno v:
Journal of Pain Research, Vol 2014, Iss default, Pp 679-687 (2014)
Philip J Mease,1 Daniel J Clauw,2 Joel M Trugman,3 Robert H Palmer,3 Yong Wang3 1Swedish Medical Center and University of Washington, Seattle, WA, USA; 2Chronic Pain and Fatigue Research Center, University of Michigan Health System, Ann Arbor, MI, US
Externí odkaz:
https://doaj.org/article/5d01783b08464d24b088f08db3de58ca
Autor:
Merola, JF, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gossec, L, Gottlieb, AB, Thaçi, D, Warren, RB, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J, Coates, LC
Publikováno v:
The Lancet, 401(10370), 38-48. Elsevier Limited
Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with placebo over 16 weeks in patients with active psoriatic arthritis and pre
Autor:
Ritchlin, CT, Coates, LC, McInnes, IB, Mease, PJ, Merola, JF, Tanaka, Y, Asahina, A, Gossec, L, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Landewé, R
Objectives: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ treatment has demonstrated superior efficacy versus placebo (PBO) at Week 16 in biologic disease‑modifying ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::0ae8f298a66cfb33a4fb1de689e01e8c
https://ora.ox.ac.uk/objects/uuid:24f30bf1-7136-47c4-8f1d-af2f12c9bbad
https://ora.ox.ac.uk/objects/uuid:24f30bf1-7136-47c4-8f1d-af2f12c9bbad
Autor:
de Vlam, K, Mease, PJ, Bushmakin, AG, Fleischmann, R, Ogdie, A, Azevedo, VF, Merola, JF, Woolcott, J, Cappelleri, JC, Fallon, L, Taylor, PC
Publikováno v:
Rheumatology and Therapy. 9:1451-1464
Introduction:Pain is a multidimensional factor and core domain of psoriatic arthritis (PsA). This analysis aimed to quantify the role of potential inflammation-associated outcomes on pain reduction in patients with PsA receiving tofacitinib, using me
Autor:
Strand, V, Kaeley, GS, Bergman, MJ, Gladman, DD, Coates, LC, Sherif, B, Hur, P, Parikh, B, Gilloteau, I, Mease, PJ
Publikováno v:
The Lancet Rheumatology. 4:e208-e219
Background: The phase 3 FUTURE 5 trial (NCT02404350) showed the clinical and radiographical efficacy of secukinumab in patients with psoriatic arthritis. This analysis aimed to assess the effect of secukinumab on patient-reported outcomes (PROs). Met
Publikováno v:
BMC Rheumatology. 6
Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post-hoc analysis of two phase III studies in patients with PsA treated with tofacitinib assessed dactylitis by location, and the impact on
Autor:
Coates, LC, Abraham, S, Tillett, W, Mease, PJ, Ramiro, S, Wu, T, Wang, X, Pangan, AL, Song, I-H
Publikováno v:
Coates, L C, Abraham, S, Tillett, W, Mease, P J, Ramiro, S, Wu, T, Wang, X, Pangan, A L & Song, I-H 2022, ' Performance and Predictors of Minimal Disease Activity Response in Peripheral Spondyloarthritis Patients Treated With Adalimumab ', Arthritis Care & Research, vol. 74, no. 2, pp. 259-267 . https://doi.org/10.1002/acr.24442
Objectives: To examine concurrent validity and discrimination of modified minimal disease activity (mMDA) criteria in peripheral spondyloarthritis (pSpA) following OMERACT filter principles and determine predictors of mMDA response. Methods: Four mMD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::13be3b147aa8a950ba7b04e359b4b6f5
https://purehost.bath.ac.uk/ws/files/211978631/AC_R_mMDA_in_pSpA_manuscript_accepted.pdf
https://purehost.bath.ac.uk/ws/files/211978631/AC_R_mMDA_in_pSpA_manuscript_accepted.pdf
Autor:
Coates, LC, Ritchlin, CT, Gossec, L, Helliwell, P, Rahman, P, Hsia, EC, Kollmeier, A, Xu, XL, Karyekar, C, Shawi, M, Noel, W, Jiang, Y, Sheng, S, Wang, Y, Mease, PJ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::c02d2b289a4434dcecd7cb2fb49c133d
https://doi.org/10.1136/annrheumdis-2021-eular.167
https://doi.org/10.1136/annrheumdis-2021-eular.167
Publikováno v:
Seminars in Arthritis and Rheumatism. 55:152023
Biosimilars represent a novel category in the world of follow-up medicinal products with the requirement that they are highly similar but not identical to an approved originator biologic medicine, with no clinically meaningful differences in safety,